151 related articles for article (PubMed ID: 15790464)
1. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
Lewin SN; Mutch DG; Whitcomb BP; Liapis H; Herzog TJ
Gynecol Oncol; 2005 Apr; 97(1):228-33. PubMed ID: 15790464
[TBL] [Abstract][Full Text] [Related]
2. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
Gross M; Hiesse C; Kriaa F; Goldwasser F
Anticancer Drugs; 1999 Jul; 10(6):533-6. PubMed ID: 10885900
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma.
Kalra N; Kad R; Osama S
Int J Clin Oncol; 2007 Oct; 12(5):385-7. PubMed ID: 17929123
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
Lee HW; Chung MJ; Kang H; Choi H; Choi YJ; Lee KJ; Lee SW; Han SH; Kim JS; Song SY
Gut Liver; 2014 Jan; 8(1):109-12. PubMed ID: 24516709
[TBL] [Abstract][Full Text] [Related]
5. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
6. Haemolytic uraemic syndrome associated with gemcitabine.
Moya-Horno I; Querol Niñerola R; Bonfill Abella T; Dalmau Pórtulas E; Gallardo-Díaz E; Saigí Grau E; Pericay Pijaume C
Clin Transl Oncol; 2010 May; 12(5):381-3. PubMed ID: 20466623
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
8. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report.
Citarrella P; Gebbia V; Teresi M; Miceli S; Sciortino G; Vaglica M; Pizzardi N; Palmeri S
Anticancer Res; 2002; 22(2B):1183-5. PubMed ID: 12168922
[TBL] [Abstract][Full Text] [Related]
9. Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.
Nieto-Ríos JF; Zuluaga-Quintero M; Higuita LM; Rincón CI; Galvez-Cárdenas KM; Ocampo-Kohn C; Aristizabal-Alzate A; Florez-Vargas AA; Zuluaga-Valencia GA
J Bras Nefrol; 2016 Jun; 38(2):255-9. PubMed ID: 27438981
[TBL] [Abstract][Full Text] [Related]
10. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
Saif MW; McGee PJ
JOP; 2005 Jul; 6(4):369-74. PubMed ID: 16006690
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.
López Rubio ME; Rodado Martínez R; Illescas ML; Mateo Bosch E; Martinez Díaz M; de la Vara Inesta L; Cabezuelo B; Morales Albuja ME; Lucas Guillén E; Jimeno García L
Clin Nephrol; 2017 Feb; 87 (2017)(2):100-106. PubMed ID: 27879189
[TBL] [Abstract][Full Text] [Related]
12. [Hemolytic uremic syndrome following gemcitabine treatment].
Bourquin V; Guinand A; Haenni C; Giovannini M; Delouche D; Dettwiler S; Moll S
Rev Med Suisse; 2008 Apr; 4(154):1056-61. PubMed ID: 18557535
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-associated hemolytic-uremic syndrome.
Walter RB; Joerger M; Pestalozzi BC
Am J Kidney Dis; 2002 Oct; 40(4):E16. PubMed ID: 12324937
[TBL] [Abstract][Full Text] [Related]
14. [Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Desramé J; Duvic C; Bredin C; Béchade D; Artru P; Brézault C; Defuentes G; Poirier JM; Dourthe LM; Coutant G; Chaussade S; de Gramont A; Algayres JP
Rev Med Interne; 2005 Mar; 26(3):179-88. PubMed ID: 15777580
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
[TBL] [Abstract][Full Text] [Related]
17. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
Fung MC; Storniolo AM; Nguyen B; Arning M; Brookfield W; Vigil J
Cancer; 1999 May; 85(9):2023-32. PubMed ID: 10223245
[TBL] [Abstract][Full Text] [Related]
18. Is thrombotic microangiopathy associated with antitumoral activity?
Chopin N; Alexandre J; Chapron C; Moachon L; Goldwasser F
Gynecol Oncol; 2006 Jun; 101(3):549-50. PubMed ID: 16527338
[No Abstract] [Full Text] [Related]
19. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
Skarlos DV; Kalofonos HP; Fountzilas G; Dimopoulos MA; Pavlidis N; Razis E; Economopoulos T; Pectasides D; Gogas H; Kosmidis P; Bafaloukos D; Klouvas G; Kyratzis G; Aravantinos G
Anticancer Res; 2005; 25(4):3103-8. PubMed ID: 16080573
[TBL] [Abstract][Full Text] [Related]
20. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Müller S; Schütt P; Bojko P; Nowrousian MR; Hense J; Seeber S; Moritz T
Ann Hematol; 2005 Feb; 84(2):110-4. PubMed ID: 15340761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
